Join to View Full Profile
Dana-Farber Cancer InstituteBoston, MA 02127
Dr. Torchia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford University School of MedicineClass of 2015
Certifications & Licensure
MA State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Novel Antimurine Thyroid-Stimulating Hormone Receptor Monoclonal Antibodies.Alyssa N Klee, James A Torchia, Gordon J Freeman
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2023-06-01 - 10 citationsThe CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.Apoorvi Chaudhri, Xia Bu, Yunfei Wang, Michael Gomez, James A Torchia
Frontiers in Immunology. 2023-01-01 - 14 citationsOptimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo.James A Torchia, Alexander H Tavares, Laura S Carstensen, Da-Yuan Chen, Jessie Huang
Science Advances. 2022-12-09
Press Mentions
Breakthrough! Receptor “Decoy” Drug Neutralizes COVID-19 Virus Together with Omicron and Different VariantsDecember 26th, 2022- New Receptor “Decoy” Drug Neutralizes COVID-19 Virus and Its VariantsDecember 7th, 2022
- Experimental Decoy Drug Tricks Coronavirus, Then Destroys ItDecember 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
